Catalyst
Slingshot members are tracking this event:
Pfizer's (PFE) Supplemental New Drug Application for Ibrance/Letrozole in Postmenopausal Women with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative (ER+, HER2-) Metastatic Breast Cancer Accepted for FDA Review
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PFE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 21, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Supplemental New Drug Application, Ibrance, Letrozole, Postmenopausal Women With Hr+ Mbc, Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2, Er+, Her2-, Her2- Metastatic Breast Cancer, Fda
